"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Ganirelix Acetate Injection
Ganirelix Acetate Injection (ganirelix) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
DOSAGE AND ADMINISTRATION
After initiating FSH therapy on Day 2 or 3 of the cycle, Ganirelix Acetate Injection (ganirelix) 250 µg may be administered subcutaneously once daily during the mid to late portion of the follicular phase. By taking advantage of endogenous pituitary FSH secretion, the requirement for exogenously administered FSH may be reduced. Treatment with Ganirelix Acetate should be continued daily until the day of hCG administration. When a sufficient number of follicles of adequate size are present, as assessed by ultrasound, final maturation of follicles is induced by administering hCG. The administration of hCG should be withheld in cases where the ovaries are abnormally enlarged on the last day of FSH therapy to reduce the chance of developing OHSS (Ovarian Hyperstimulation Syndrome).
Directions for Using Ganirelix Acetate Injection
- Ganirelix Acetate Injection (ganirelix) is supplied in a sterile, prefilled syringe and is intended for SUBCUTANEOUS administration only.
- Wash hands thoroughly with soap and water.
- The most convenient sites for SUBCUTANEOUS injection are in the abdomen around the navel or upper thigh.
- The injection site should be swabbed with a disinfectant to remove any surface bacteria. Clean about two inches around the point where the needle will be inserted and let the disinfectant dry for at least one minute before proceeding.
- With syringe held upward, remove needle cover.
- Pinch up a large area of skin between the finger and thumb. Vary the injection site a little with each injection.
- The needle should be inserted at the base of the pinched-up skin at an angle of 45-the skin surface.
- When the needle is correctly positioned, it will be difficult to draw back on the plunger. If any blood is drawn into the syringe, the needle tip has penetrated a vein or artery. If this happens, withdraw the needle slightly and reposition the needle without removing it from the skin. Alternatively, remove the needle and use a new, sterile, prefilled syringe. Cover the injection site with a swab containing disinfectant and apply pressure; the site should stop bleeding within one or two minutes.
- Once the needle is correctly placed, depress the plunger slowly and steadily, so the solution is correctly injected and the skin is not damaged.
- Pull the syringe out quickly and apply pressure to the site with a swab containing disinfectant. 11. Use the sterile, prefilled syringe only once and dispose of it properly.
Ganirelix Acetate Injection (ganirelix) is supplied in:
Disposable, sterile, prefilled 1 mL glass syringes containing 250 µg/0.5 mL of Ganirelix Acetate. Each Ganirelix Acetate sterile, prefilled syringe is affixed with a 27 gauge x ½inch needle and is blister-packed.
Single syringe..............NDC 0052-0301-51
Store at 25° C (77° F); excursions permitted to 15-30° C (59-86° F) [see USP Controlled Room Temperature]. Protect from light.
Manufactured for Organon USA Inc. Roseland, NJ 07068 by Vetter Pharma-Fertigung GmbH & Co. KG Ravensburg, Germany and packaged by Organon (Ireland) Ltd. Swords, Co. Dublin, Ireland. FDA Rev date: 06/30/08
Last reviewed on RxList: 8/1/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Ganirelix Acetate Injection Information
Ganirelix Acetate Injection - User Reviews
Ganirelix Acetate Injection User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Find out what women really need.